JP5635727B2 - チアゾリルmglur5アンタゴニスト及びそれらの使用のための方法 - Google Patents
チアゾリルmglur5アンタゴニスト及びそれらの使用のための方法 Download PDFInfo
- Publication number
- JP5635727B2 JP5635727B2 JP2007543041A JP2007543041A JP5635727B2 JP 5635727 B2 JP5635727 B2 JP 5635727B2 JP 2007543041 A JP2007543041 A JP 2007543041A JP 2007543041 A JP2007543041 A JP 2007543041A JP 5635727 B2 JP5635727 B2 JP 5635727B2
- Authority
- JP
- Japan
- Prior art keywords
- thiazol
- methyl
- ethynyl
- mmol
- disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- XNFNSIIVOBBRLZ-UHFFFAOYSA-N CC(C)Oc(nc1)ncc1C#Cc1c[s]c(C)n1 Chemical compound CC(C)Oc(nc1)ncc1C#Cc1c[s]c(C)n1 XNFNSIIVOBBRLZ-UHFFFAOYSA-N 0.000 description 1
- SYOSUEIMOYEGKU-UHFFFAOYSA-N Cc1nc(C#Cc(cc2)cnc2-c2cc(C#N)cc(F)c2)c[s]1 Chemical compound Cc1nc(C#Cc(cc2)cnc2-c2cc(C#N)cc(F)c2)c[s]1 SYOSUEIMOYEGKU-UHFFFAOYSA-N 0.000 description 1
- PYMPQHSJRUVZKT-UHFFFAOYSA-N Cc1nc(C#Cc(cc2)cnc2Cl)c[s]1 Chemical compound Cc1nc(C#Cc(cc2)cnc2Cl)c[s]1 PYMPQHSJRUVZKT-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N OC(C(F)(F)F)=O Chemical compound OC(C(F)(F)F)=O DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Description
2−クロロ−5−[(2−メチル−1,3−チアゾール−4−イル)エチニル]ピリジン
2−クロロ−5−[(2−メチル−1,3−チアゾール−4−イル)エチニル]ピリミジン
3−フルオロ−5−{5−[(2−メチル−1,3−チアゾール−4−イル)エチニル]ピリジン−2−イル}ベンゾニトリル
2−(2−フルオロフェニル)−5−[(2−メチル−1,3−チアゾール−4−イル)エチニル]ピリジン
2−(3−フルオロフェニル)−5−[(2−メチル−1,3−チアゾール−4−イル)エチニル]ピリジン
2−{5−[(2−メチル−1,3−チアゾール−4−イル)エチニル]ピリジン−2−イル}ベンゾニトリル
2−(2−メチルフェニル)−5−[(2−メチル−1,3−チアゾール−4−イル)エチニル]ピリジン
2−(5−フルオロ−2−メトキシフェニル)−5−[(2−メチル−1,3−チアゾール−4−イル)エチニル]ピリジン
2−(2−クロロフェニル)−5−[(2−メチル−1,3−チアゾール−4−イル)エチニル]ピリジン
2−(2−メトキシフェニル)−5−[(2−メチル−1,3−チアゾール−4−イル)エチニル]ピリジン
2−(4−フルオロ−2−メチルフェニル)−5−[(2−メチル−1,3−チアゾール−4−イル)エチニル]トリフルオロ酢酸ピリジニウム
2−(3,5−ジフルオロ−2−メトキシフェニル)−5−[(2−メチル−1,3−チアゾール−4−イル)エチニル]トリフルオロ酢酸ピリジニウム
2−(4−フルオロ−2−メトキシフェニル)−5−[(2−メチル−1,3−チアゾール−4−イル)エチニル]トリフルオロ酢酸ピリジニウム
2−(5−フルオロ−2−メチルフェニル)−5−[(2−メチル−1,3−チアゾール−4−イル)エチニル]トリフルオロ酢酸ピリジニウム
2−(2−メチルフェニル)−5−[(2−メチル−1,3−チアゾール−4−イル)エチニル]ピリミジン
5−[(2−メチル−1,3−チアゾール−4−イル)エチニル]−2−[2−(メチルチオ)フェニル]ピリミジン
2−(2−クロロフェニル)−5−[(2−メチル−1,3−チアゾール−4−イル)エチニル]ピリミジン
2−(2,3−ジメチルフェニル)−5−[(2−メチル−1,3−チアゾール−4−イル)エチニル]ピリミジン
1−{5−[(2−メチル−1,3−チアゾール−4−イル)エチニル]ピリジン−2−イル}−1H−ピロロ[2,3−b]ピリジン
1−{5−[(2−メチル−1,3−チアゾール−4−イル)エチニル]ピリジン−2−イル}−1H−ピロロ[2,3−c]ピリジン
5−[(2−メチル−1,3−チアゾール−4−イル)エチニル]−2−ピペリジン−1−イルピリジン
2−(2−メチルピロリジン−1−イル)−5−[(2−メチル−1,3−チアゾール−4−イル)エチル]ピリジン
2−(2−メチルピロリジン−1−イル)−5−[(2−メチル−1,3−チアゾール−4−イル)エチニル]ピリミジン
N−(tert−ブチル)−5−[(2−メチル−1,3−チアゾール−4−イル)エチニル]ピリミジン−2−アミン
2−(3−メチルピペリジン−1−イル)−5−[(2−メチル−1,3−チアゾール−4−イル)エチニル]ピリミジン
5−[(2−メチル−1,3−チアゾール−4−イル)エチニル]−2−ピペリジン−1−イルピリミジン
2−イソプロポキシ−5−[(2−メチル−1,3−チアゾール−4−イル)エチニル]ピリミジン
2−イソプロポキシ−5−[(2−メチル−1,3−チアゾール−4−イル)エチニル]トリフルオロ酢酸ピリジニウム
2−(tert−ブチルチオ)−5−[(2−メチル−1,3−チアゾール−4−イル)エチニル]ピリジン
白色の固体として2−(tert−ブチルチオ)−5−[(2−メチル−1,3−チアゾール−4−イル)エチニル]ピリミジン
2−シクロヘキシル−5−[(2−メチル−1,3−チアゾール−4−イル)エチニル]ピリジン
2−tert−ブチル−5−[(2−メチル−1,3−チアゾール−4−イル)エチニル]ピリジン
2−シクロヘキシル−5−[(2−メチル−1,3−チアゾール−4−イル)エチニル]ピリミジン
上記及び当該技術分野の当業者には周知の同様の合成方法を使用し、次の化合物を調製した。
カルシウムフラックスアッセイ
マウスの繊維芽Ltk−細胞中で安定して発現するhmGluR5a受容体に対し、化合物の活性を調べた(hmGluR5a/L38−20細胞株)。一般的には、Daggett et al.,Neuropharmacology 34:871−886(1995)を参照されたい。蛍光性カルシウム感受性色素を使用して測定した細胞内カルシウム([Ca2+])中の変化により、受容体活性を検出し、fura−2、hmGluR5a/L38−20細胞を、96ウェルプレート上に播種し、3M fura−2を1時間にわたって与えた。取り込まれなかった色素を細胞から洗浄し、全自動プレート処理及び液体配送システム中に組み込まれた特注の96チャンネル蛍光光度計(SIBIA−SAIC、La Jolla、CA)ヘ、細胞プレートを移した。光学フィルターと結合したキセノン源を用い、細胞が350nm及び385nmにて活性化した。2色性反射鏡及び510nmの干渉フィルターを通して、放射光を試料から集光し、冷却されたCCDカメラ(Princeton Indtruments)中に誘導した。映像対を、およそ1秒ごとに捕捉し、背景を差し引いた後に比率イメージを得た。20秒の基底の読み取り後、EC80濃度のグルタミン酸(10 M)をウェルに加え、更なる60秒間、反応を評価した。化合物のスクリーニングの下で、[Ca2+]iのグルタミン酸誘発の増加を、グルタミン酸のみの反応と比較した(陽性対照)。
齧歯動物の脳膜へ結合する[3H]−mGluR5アンタゴニスト
Anderson JJ、Rao SP、Rowe B、Giracello DR、Holtz G、Chapman DF、Tehrani L、Bradbury MJ、Cosford ND、Varney MA、[3H]Methoxymethyl−3−[(2−methyl−1,3−thiazol−4−yl)ethynyl]pyridine binding to metabotropic glutamate receptor subtype 5 in rodent brain:in vitro and in vivo characterization(齧歯動物の脳における代謝調節型グルタミン酸受容体サブタイプ5へ結合する[3H]メトキシメチル−3−[(2−メチル−1,3−チアゾール−4−イル)エチニル]ピリジン:インビトロ及びインビボの性質決定)、J Pharmacol Exp Ther.2002年12月;303(3):1044−51に従って、全ラット脳、或いはmGlu5+/+又はmGlu5−/−全マウス脳を使用し、膜を調製した(Ransom RW及びStec NL(1988)Cooperative modulation of [3H]MK−801 binding to the N−methyl−D−aspartate receptor−ion channel complex by L−glutamate, glycine and polyamines、J Neurochem 51:830−836に記載どおり)。
ホスファチジルイノシトール加水分解(IP)アッセイ
Berridge et al.(1982)(Berridge et al.(1982)Biochem.J.206:587−5950及びNakajima et al.J.Biol.Chem.267:2437−2442(1992))に記載どおり、僅かな修正を用い、イノシトールリン酸アッセイを実行した。hmGluR5(hmGluR5/L38−20細胞)を発現するマウスの繊維芽Ltk細胞を、8×105細胞/ウェルの密度にて、24ウェルプレート中に播種した。[3H]−イノシトール1Ci(Amersham PT6−271、Arlington Heights、IL、比活性度=17.7Ci/mmol)を各ウェルに加え、37℃で16時間インキュベートした。細胞を2回洗浄し、標準的Hepes緩衝生理的食塩水バッファ0.5mL中(HBS、125mM NaCl、5mM KCl、0.62M MgSO4、1.8mM CaCl2、20mM HEPES、6mM グルコース、pHを7.4へ)で、45分間インキュベートした。細胞を10mM LiClを含有するHBSで洗浄し、400iilのバッファを各ウェルに加えた。細胞を37℃で20分間インキュベートした。検査に対し、10×本発明の実施において使用される化合物50L[HBS/LiCl(100mM)中で生成]を添加し、10分間インキュベートした。10pMのグルタミン酸を添加することにより、細胞を活性化し、プレートを37℃で1時間放置した。
代表的な化合物の活性
前述の実施例で開示された特定の化合物の活性が下記に示されている(N.D.=測定なし):
Claims (2)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61680504P | 2004-10-07 | 2004-10-07 | |
US60/616,805 | 2004-10-07 | ||
PCT/US2005/035921 WO2007050050A2 (en) | 2004-10-07 | 2005-10-06 | Thiazolyl mglur5 antagonists and methods for their use |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014184615A Division JP2015013885A (ja) | 2004-10-07 | 2014-09-10 | チアゾリルmglur5アンタゴニスト及びそれらの使用のための方法 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2008516004A JP2008516004A (ja) | 2008-05-15 |
JP2008516004A5 JP2008516004A5 (ja) | 2014-10-30 |
JP5635727B2 true JP5635727B2 (ja) | 2014-12-03 |
Family
ID=37968242
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007543041A Active JP5635727B2 (ja) | 2004-10-07 | 2005-10-06 | チアゾリルmglur5アンタゴニスト及びそれらの使用のための方法 |
JP2014184615A Pending JP2015013885A (ja) | 2004-10-07 | 2014-09-10 | チアゾリルmglur5アンタゴニスト及びそれらの使用のための方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014184615A Pending JP2015013885A (ja) | 2004-10-07 | 2014-09-10 | チアゾリルmglur5アンタゴニスト及びそれらの使用のための方法 |
Country Status (9)
Country | Link |
---|---|
US (3) | US7879882B2 (ja) |
EP (2) | EP2380889B1 (ja) |
JP (2) | JP5635727B2 (ja) |
CN (1) | CN101223166B (ja) |
AT (1) | ATE520692T1 (ja) |
AU (1) | AU2005336513B2 (ja) |
CA (1) | CA2583572C (ja) |
ES (1) | ES2369783T3 (ja) |
WO (1) | WO2007050050A2 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015013885A (ja) * | 2004-10-07 | 2015-01-22 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | チアゾリルmglur5アンタゴニスト及びそれらの使用のための方法 |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8349852B2 (en) | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
TW201124391A (en) * | 2009-10-20 | 2011-07-16 | Lundbeck & Co As H | 2-substituted-ethynylthiazole derivatives and uses of same |
AR080055A1 (es) | 2010-02-01 | 2012-03-07 | Novartis Ag | Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de los receptores de crf -1 |
WO2011092293A2 (en) | 2010-02-01 | 2011-08-04 | Novartis Ag | Cyclohexyl amide derivatives as crf receptor antagonists |
JP5748777B2 (ja) | 2010-02-02 | 2015-07-15 | ノバルティス アーゲー | Crf受容体アンタゴニストとしてのシクロヘキシルアミド誘導体 |
US8420661B2 (en) * | 2010-04-13 | 2013-04-16 | Hoffmann-La Roche Inc. | Arylethynyl derivatives |
US8772300B2 (en) * | 2011-04-19 | 2014-07-08 | Hoffmann-La Roche Inc. | Phenyl or pyridinyl-ethynyl derivatives |
EP2702050B1 (en) * | 2011-04-26 | 2016-05-18 | F.Hoffmann-La Roche Ag | Pyrazolidin-3-one derivatives |
HUE025031T2 (en) * | 2011-04-26 | 2016-02-29 | Hoffmann La Roche | Ethinyl derivatives as positive allosteric modulators of MGLUR5 |
WO2014121883A1 (en) | 2013-02-07 | 2014-08-14 | Merck Patent Gmbh | Substituted acetylene derivatives and their use as positive allosteric modulators of mglur4 |
UA116023C2 (uk) * | 2013-07-08 | 2018-01-25 | Ф. Хоффманн-Ля Рош Аг | Етинільні похідні як антагоністи метаботропного глутаматного рецептора |
WO2015188368A1 (en) | 2014-06-13 | 2015-12-17 | Merck Sharp & Dohme Corp. | Pyrrolo[2,3-c]pyridines as imaging agents for neurofibrilary tangles |
CN107849006B (zh) | 2015-06-03 | 2020-11-13 | 豪夫迈·罗氏有限公司 | 乙炔基衍生物 |
SG10202002990XA (en) | 2017-08-04 | 2020-05-28 | Skyhawk Therapeutics Inc | Methods and compositions for modulating splicing |
CN114007613A (zh) | 2019-02-05 | 2022-02-01 | 斯基霍克疗法公司 | 用于调节剪接的方法和组合物 |
EP3920928A4 (en) | 2019-02-06 | 2022-09-28 | Skyhawk Therapeutics, Inc. | METHODS AND COMPOSITIONS FOR MODULATION OF SPLICING |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6956049B1 (en) * | 1999-08-31 | 2005-10-18 | Merck & Co., Inc. | Methods of modulating processes mediated by excitatory amino acid receptors |
US7462619B2 (en) * | 1999-08-31 | 2008-12-09 | Merck & Co., Inc. | Pyridazine, pyrimidine and pyrazine ethyne compounds |
US7365074B2 (en) * | 1999-08-31 | 2008-04-29 | Merck & Co., Inc. | Pyridazine, pyrimidine and pyrazine ethyne compounds |
US6774138B2 (en) | 1999-08-31 | 2004-08-10 | Merck & Co., Inc. | Thiazolyl(pyridyl)ethyne compounds |
CA2383524C (en) * | 1999-08-31 | 2010-09-28 | Merck & Co., Inc. | Thiazolyl alkynyl compounds and methods of use thereof |
US6551270B1 (en) | 2000-08-30 | 2003-04-22 | Snowden Pencer, Inc. | Dual lumen access port |
US6903005B1 (en) | 2000-08-30 | 2005-06-07 | Micron Technology, Inc. | Method for the formation of RuSixOy-containing barrier layers for high-k dielectrics |
CA2503245A1 (en) * | 2002-10-24 | 2004-05-06 | Merck & Co., Inc. | Alkyne derivatives as tracers for metabotropic glutamate receptor binding |
EP2380889B1 (en) | 2004-10-07 | 2013-06-26 | Merck Sharp & Dohme Corp. | Thiazolyl MGLUR5 antagonists and methods for their use |
-
2005
- 2005-10-06 EP EP11167527.8A patent/EP2380889B1/en active Active
- 2005-10-06 EP EP05858618A patent/EP1893608B1/en active Active
- 2005-10-06 CA CA2583572A patent/CA2583572C/en active Active
- 2005-10-06 CN CN2005800415189A patent/CN101223166B/zh active Active
- 2005-10-06 AT AT05858618T patent/ATE520692T1/de not_active IP Right Cessation
- 2005-10-06 WO PCT/US2005/035921 patent/WO2007050050A2/en active Application Filing
- 2005-10-06 US US11/664,902 patent/US7879882B2/en active Active
- 2005-10-06 AU AU2005336513A patent/AU2005336513B2/en not_active Ceased
- 2005-10-06 ES ES05858618T patent/ES2369783T3/es active Active
- 2005-10-06 JP JP2007543041A patent/JP5635727B2/ja active Active
-
2011
- 2011-01-28 US US13/016,304 patent/US8242143B2/en active Active
-
2012
- 2012-07-26 US US13/558,537 patent/US8609852B2/en active Active
-
2014
- 2014-09-10 JP JP2014184615A patent/JP2015013885A/ja active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015013885A (ja) * | 2004-10-07 | 2015-01-22 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | チアゾリルmglur5アンタゴニスト及びそれらの使用のための方法 |
Also Published As
Publication number | Publication date |
---|---|
EP2380889A3 (en) | 2012-01-18 |
ES2369783T3 (es) | 2011-12-05 |
US8242143B2 (en) | 2012-08-14 |
CN101223166B (zh) | 2011-10-19 |
AU2005336513A1 (en) | 2007-05-17 |
CA2583572A1 (en) | 2006-04-07 |
WO2007050050A2 (en) | 2007-05-03 |
AU2005336513B2 (en) | 2012-08-09 |
JP2015013885A (ja) | 2015-01-22 |
US20120289696A1 (en) | 2012-11-15 |
CN101223166A (zh) | 2008-07-16 |
US7879882B2 (en) | 2011-02-01 |
WO2007050050A3 (en) | 2008-02-07 |
JP2008516004A (ja) | 2008-05-15 |
EP2380889B1 (en) | 2013-06-26 |
CA2583572C (en) | 2016-07-12 |
EP1893608A2 (en) | 2008-03-05 |
EP1893608A4 (en) | 2009-04-22 |
EP2380889A2 (en) | 2011-10-26 |
US8609852B2 (en) | 2013-12-17 |
AU2005336513A8 (en) | 2009-01-08 |
ATE520692T1 (de) | 2011-09-15 |
EP1893608B1 (en) | 2011-08-17 |
US20110230526A1 (en) | 2011-09-22 |
US20090203903A1 (en) | 2009-08-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5635727B2 (ja) | チアゾリルmglur5アンタゴニスト及びそれらの使用のための方法 | |
US7371767B2 (en) | Heteroaryl substituted pyrrole modulators of metabotropic glutamate receptor-5 | |
JP4815083B2 (ja) | 複素環化合物およびそれの使用方法 | |
JP5636434B2 (ja) | アルファ7正のアロステリックモジュレーターとしてのモルホリノチアゾール | |
JP7094989B2 (ja) | シクロプロピルウレアホルミルペプチド2受容体およびホルミルペプチド1受容体アゴニスト | |
JP6800885B2 (ja) | イミダゾピラジン及びピラゾロピリミジン、並びにampa受容体調節物質としてのこれらの使用 | |
JP2010531848A (ja) | オレキシン受容体アンタゴニストとして有用なピペリジン誘導体 | |
US7105533B2 (en) | Fused heterobicyclo substituted phenyl metabotropic glutamate-5 modulators | |
GB2563642A (en) | Small molecule modulators of human STING | |
JP2013515032A (ja) | 二置換ヘテロアリール縮合ピリジン類 | |
WO2007037543A1 (ja) | ビアリールアミド誘導体 | |
JP2017522277A (ja) | 代謝型グルタミン酸受容体の負のアロステリックモジュレーター(nams)とその使用 | |
TW201930270A (zh) | 吡唑化合物 | |
JP2021529746A (ja) | 心臓サルコメア阻害剤 | |
JP3351748B2 (ja) | 2,3−ジ置換−(5,6)−ヘテロアリール縮合−ピリミジン−4−オンの新規なアトロプ異性体 | |
GB2572526A (en) | Heterocyclic small molecule modulators of human STING | |
JPWO2015060348A1 (ja) | 縮合ピラゾール誘導体 | |
WO2012151138A1 (en) | Cyclohexene benzotriazole derivatives | |
JP2016204374A (ja) | 縮合ピラゾール誘導体からなる医薬 | |
CA2927152C (en) | Phenyl linked quinolinyl modulators of ror-gamma-t | |
AU2012208981A1 (en) | Thiazolyl mGluR5 antagonists and methods for their use | |
CN101747327B (zh) | 芳酰胺基噻唑类衍生物及其制备方法和用途 | |
WO2017198180A1 (zh) | 一类含氟三氮唑并吡啶类化合物及其制备方法、药物组合物和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20081003 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20111108 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120202 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120209 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120508 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20120508 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120605 |
|
RD07 | Notification of extinguishment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7427 Effective date: 20120618 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20121009 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20130223 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130321 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140606 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140611 |
|
A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20140910 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20141017 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5635727 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |